The deal gives Merck access to Acceleron's rare disease drug candidate, sotatercept, which the company expects could bring in billions of dollars in sales, and comes as Keytruda moves toward the loss of market exclusivity in 2028. (The Merck logo is seen at a gate to the Merck & Co campus in Rahway, New Jersey, U.S. - Reuters filepic)
NEW YORK: Merck & Co said on Thursday it would buy Acceleron Pharma Inc for about $11.5 billion, broadening its portfolio beyond aging cancer drug Keytruda with potential treatments that could bring in fresh revenue.
The deal gives Merck access to Acceleron's rare disease drug candidate, sotatercept, which the company expects could bring in billions of dollars in sales, and comes as Keytruda moves toward the loss of market exclusivity in 2028.
